Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2013 Dec;2(1):52.
doi: 10.1186/2193-1801-2-52. Epub 2013 Feb 15.

CYP2D6 Genotypes, Endoxifen Levels, and Disease Recurrence in 224 Filipino and Vietnamese Women Receiving Adjuvant Tamoxifen for Operable Breast Cancer

Free PMC article
Case Reports

CYP2D6 Genotypes, Endoxifen Levels, and Disease Recurrence in 224 Filipino and Vietnamese Women Receiving Adjuvant Tamoxifen for Operable Breast Cancer

Richard R Love et al. Springerplus. .
Free PMC article


Background: While tamoxifen activity is mainly due to endoxifen and the concentration of this active metabolite is, in part, controlled by CYP2D6 metabolic status, clinical correlative studies have produced mixed results.

Findings: In an exploratory study, we determined the CYP2D6 metabolic status and plasma concentrations of endoxifen among 224 Filipino and Vietnamese women participating in a clinical trial of adjuvant hormonal therapy for operable breast cancer. We further conducted a nested-case-control study among 48 women (half with recurrent disease, half without) investigating the relationship of endoxifen concentrations and recurrence of disease. We found a significant association of reduced endoxifen plasma concentrations with functionally important CYP2D6 genotypes. High endoxifen concentrations were associated with higher risk of recurrence; with a quadratic trend fitted to a stratified Cox proportional hazards regression model, the likelihood ratio p-value was 0.002. The trend also showed that in 8 out of 9 pairs with low endoxifen concentrations, the recurrent case had lower endoxifen levels than the matched control.

Conclusions: This exploratory analysis suggests that there is an optimal range for endoxifen concentrations to achieve favorable effects as adjuvant therapy. In particular, at higher concentrations (>70, endoxifen may promote recurrence.


Figure 1
Figure 1
Endoxifen plasma concentrations by CYP2D6 genotype metabolic status in Filipino (n = 138) and Vietnamese (n = 86) patients (p = 0.0001 for trend: normal > intermediate > slow).
Figure 2
Figure 2
Plot of the absolute difference in endoxifen levels between members of each matched pair by the endoxifen level of the recurrence member of the matched pair.

Similar articles

See all similar articles

Cited by 11 articles

See all "Cited by" articles


    1. Ahamed A, Ali SM, Ahmad MU, et al. Orally administered endoxifen is a new therapeutic agent for breast cancer. Breast Cancer Res Treat. 2010;122:579–584. doi: 10.1007/s10549-009-0704-7. - DOI - PubMed
    1. Bergstralh E, Kosanke J, Jacobsen S. Software for optimal matching in observational studies. Epidemiology. 1996;7(3):331–332. - PubMed
    1. Borges S, Desta Z, Li L, Skaar TC, Ward BA, Nguyen A, Jin Y, Storniolo AM, Nikoloff DM, Wu L, Hillman G, Hayes DF, Stearns V, Flockhart DA. Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin Pharmacol Ther. 2006;80:61–74. doi: 10.1016/j.clpt.2006.03.013. - DOI - PubMed
    1. Bradford LD. CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics. 2002;3:229–243. doi: 10.1517/14622416.3.2.229. - DOI - PubMed
    1. Desta Z, Ward BA, Soukhova NV, et al. Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004;310:1062–1075. doi: 10.1124/jpet.104.065607. - DOI - PubMed

Publication types

LinkOut - more resources